Nutrivention Trial Update | Urvi Shah, MD | IMS 2023

Hi, I'm Urvi Shah, hematologist and oncologist on the Myeloma Service at Memorial Sloan Kettering Cancer Center, and I wanted to share a few updates on our Neutrivention trial, which you may have already heard about the early parts of it. So the study has completed enrollment and all patients have finished one year on the study as well. We had totally 20 patients that we were to enroll. We had three dropouts and patients who were replaced. So in total, 23 patients joined the study and 18 completed one year on the study. So far in terms of the microbiome data, we do see that from baseline to 12 weeks, so after the intervention, there was an improvement in the diversity of the microbiome as well as improvement in the relative abundance of butyrate producers in the stool. What this suggests is that we were able to, with the dietary intervention, successfully improve microbiome composition and diversity. However, whether this has an effect on the trajectory of myeloma development has not yet been directly studied. In our study, we also, patients also had weight loss of about 6% or so at 12 weeks and this weight loss was sustained at one year as well. This was a study that enrolled patients with an elevated BMI, so patients over BMI of 25. We also saw an improvement in insulin resistance and LDL cholesterol levels as well. What we are now looking at is we looked at quality of life most recently and while MGUS and smoldering myeloma patients overall are healthy and have not so many comorbidities or low quality of life, in the scores that had room for improvement, we saw an improvement in global health status, meaning overall quality of life, as well as dyspnea or shortness of breath and fatigue scores. What we are now also looking at is that there were two patients who had and progressing or a rising M-spike trajectory and we were able to look at the change in M-spike per month and see a maybe potential slowing of the M-spike trajectory for two patients. While this is still early data, it is exciting to see that there is changes in biomarkers around the disease that we know are associated with progression and we look forward to finishing up the correlative analysis for this study and working towards publishing it soon.